Cabot (NYSE:CBT) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Cabot (NYSE:CBTFree Report) from a buy rating to a hold rating in a research note released on Saturday morning.

Several other brokerages have also recently commented on CBT. Mizuho boosted their price target on Cabot from $80.00 to $90.00 and gave the stock a “neutral” rating in a research report on Thursday, June 25th. UBS Group raised their price objective on Cabot from $81.00 to $86.00 and gave the company a “neutral” rating in a report on Friday, May 8th. Truist Financial assumed coverage on shares of Cabot in a research note on Monday, June 8th. They set a “buy” rating and a $98.00 target price on the stock. JPMorgan Chase & Co. upped their target price on shares of Cabot from $68.00 to $70.00 and gave the stock an “underweight” rating in a report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Cabot in a research report on Tuesday, May 26th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $85.80.

Get Our Latest Report on CBT

Cabot Trading Down 0.1%

CBT stock opened at $88.11 on Friday. Cabot has a 12-month low of $58.33 and a 12-month high of $94.53. The business’s 50-day moving average is $87.89 and its 200 day moving average is $79.39. The company has a current ratio of 1.45, a quick ratio of 0.96 and a debt-to-equity ratio of 0.51. The stock has a market cap of $4.55 billion, a price-to-earnings ratio of 16.66, a PEG ratio of 11.46 and a beta of 0.83.

Cabot (NYSE:CBTGet Free Report) last announced its earnings results on Tuesday, May 5th. The specialty chemicals company reported $1.61 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.14. Cabot had a return on equity of 21.33% and a net margin of 7.97%.The business had revenue of $904.00 million during the quarter, compared to analysts’ expectations of $900.30 million. During the same quarter in the prior year, the firm earned $1.90 earnings per share. The business’s revenue was down 3.4% compared to the same quarter last year. Cabot has set its FY 2026 guidance at 6.000-6.50 EPS. On average, sell-side analysts anticipate that Cabot will post 6.35 EPS for the current fiscal year.

Cabot Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be given a $0.4725 dividend. The ex-dividend date is Friday, August 28th. This represents a $1.89 dividend on an annualized basis and a dividend yield of 2.1%. Cabot’s dividend payout ratio is 35.73%.

Hedge Funds Weigh In On Cabot

Institutional investors have recently added to or reduced their stakes in the stock. Norges Bank purchased a new stake in shares of Cabot in the fourth quarter valued at about $49,662,000. AQR Capital Management LLC increased its position in Cabot by 123.0% during the second quarter. AQR Capital Management LLC now owns 867,946 shares of the specialty chemicals company’s stock worth $65,096,000 after purchasing an additional 478,702 shares during the last quarter. UBS Group AG raised its stake in Cabot by 186.7% during the third quarter. UBS Group AG now owns 593,510 shares of the specialty chemicals company’s stock worth $45,136,000 after purchasing an additional 386,514 shares during the period. Pacer Advisors Inc. raised its stake in Cabot by 3,165.7% during the fourth quarter. Pacer Advisors Inc. now owns 229,252 shares of the specialty chemicals company’s stock worth $15,195,000 after purchasing an additional 222,232 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Cabot in the 4th quarter valued at about $8,785,000. Hedge funds and other institutional investors own 93.18% of the company’s stock.

About Cabot

(Get Free Report)

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.

Recommended Stories

Analyst Recommendations for Cabot (NYSE:CBT)

Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.